{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:48:19Z","timestamp":1793137699149,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clgc.2025.102363","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T19:39:24Z","timestamp":1744918764000},"page":"102363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Sensitivity and Specificity of Total Prostate Specific Antigen in the Diagnosis of Prostate Cancer in a Resource-Limited African Setting: A 5-Year Review in a Kenyan Hospital"],"prefix":"10.1016","volume":"23","author":[{"given":"Chinonso P.","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsamayem G.T.","family":"Sop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-1599","authenticated-orcid":false,"given":"Tanyi J.","family":"Tanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somo J.","family":"Lambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ndonku A.","family":"Signang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Irungu","family":"Juma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102363_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2025.102363_sbref0002","series-title":"Prostate Cancer [Internet]","article-title":"The Epidemiology of Prostate Cancer","author":"Giona","year":"2021"},{"key":"10.1016\/j.clgc.2025.102363_bib0003","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.juro.2014.04.017","article-title":"High prevalence of screen-detected prostate cancer in West Africans: implications for racial disparity of prostate cancer","volume":"192","author":"Hsing","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102363_bib0004","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/S0022-5347(01)64966-8","article-title":"Prostate cancer in Nigerians: facts and nonfacts","volume":"157","author":"Osegbe","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102363_bib0005","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12301-022-00273-y","article-title":"A comparison of clinicopathologic features of prostate cancer between Nigerian and South African black men","volume":"28","author":"Ahmed","year":"2022","journal-title":"Afr J Urol"},{"key":"10.1016\/j.clgc.2025.102363_bib0006","doi-asserted-by":"crossref","first-page":"162","DOI":"10.14740\/wjon1221","article-title":"A review of localized prostate cancer: an African perspective","volume":"10","author":"Cassell","year":"2019","journal-title":"World J Oncol"},{"key":"10.1016\/j.clgc.2025.102363_bib0007","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0065-2423(08)60334-0","article-title":"Prostatic specific antigen","volume":"31","author":"el-Shirbiny","year":"1994","journal-title":"Adv Clin Chem"},{"key":"10.1016\/j.clgc.2025.102363_bib0008","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jfma.2021.02.015","article-title":"Clinical characteristics and survival outcomes in patients with a high PSA and non-metastatic prostate cancer","volume":"121","author":"Huang","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.clgc.2025.102363_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00123","article-title":"Very early PSA response to Abiraterone in mCRPC patients: a novel prognostic factor predicting overall survival","author":"Facchini","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clgc.2025.102363_bib0010","article-title":"Dynamic changes in PSA levels predict prognostic outcomes in prostate cancer patients undergoing androgen\u2013deprivation therapy: a multicenter retrospective analysis","volume":"13","author":"Hu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2025.102363_bib0011","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2298\/ACI0704105M","article-title":"The significance of TPSA, free to total PSA ratio and PSA density in prostate carcinoma diagnostics","volume":"54","author":"Milkovic","year":"2007","journal-title":"Acta Chir Iugosl"},{"key":"10.1016\/j.clgc.2025.102363_bib0012","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0022-5347(17)38972-3","article-title":"Clinical use of prostate specific antigen in patients with prostate cancer","volume":"142","author":"Hudson","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2025.102363_bib0013","article-title":"Epidemiology of prostate cancer in Nigeria: a mixed methods systematic review","author":"Iheanacho","year":"2024","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clgc.2025.102363_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221081366","article-title":"Determination of serum prostate specific antigen levels amongst apparently healthy Nigerian males in a university and university hospital community in the Federal Capital Territory","volume":"29","author":"Aisuodionoe-Shadrach","year":"2022","journal-title":"Cancer Control"},{"key":"10.1016\/j.clgc.2025.102363_bib0015","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s12325-018-0766-1","article-title":"Prostate cancer in primary care","volume":"35","author":"Merriel","year":"2018","journal-title":"Adv Ther"},{"key":"10.1016\/j.clgc.2025.102363_bib0016","first-page":"851","article-title":"Raising cutoff value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy","volume":"139","author":"Agnihotri","year":"2014","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.clgc.2025.102363_bib0017","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF02994508","article-title":"Correlation of serum PSA and gleason score in Nigerian men with prostate cancer","volume":"14","author":"Okolo","year":"2008","journal-title":"Afr J Urol"},{"key":"10.1016\/j.clgc.2025.102363_bib0018","first-page":"802","article-title":"Prostate biopsy for elevated prostate specific antigen (PSA)\u2013Indian perspective","volume":"139","author":"Ragavan","year":"2014","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.clgc.2025.102363_bib0019","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.4103\/njcp.njcp_1643_21","article-title":"Need for age-specific prostate-specific antigen reference intervals in a Nigerian population","volume":"26","author":"Okafor","year":"2023","journal-title":"Niger J Clin Pract"},{"key":"10.1016\/j.clgc.2025.102363_bib0020","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221084932","article-title":"Prostate cancer screening, diagnostic, treatment procedures and costs in Sub-Saharan Africa: a situational analysis","volume":"29","author":"Makau-Barasa","year":"2022","journal-title":"Cancer Control"},{"key":"10.1016\/j.clgc.2025.102363_bib0021","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3329\/bmrcb.v38i3.14333","article-title":"Efficacy of lower cut-off value of serum prostate specific antigen in the diagnosis of prostate cancer","volume":"38","author":"Rashid","year":"2012","journal-title":"Bangladesh Med Res Counc Bull"},{"key":"10.1016\/j.clgc.2025.102363_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2023-000039","article-title":"Screening for prostate cancer: evidence, ongoing trials, policies, and knowledge gaps","author":"Bratt","year":"2023","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.clgc.2025.102363_bib0023","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1056\/NEJMoa031918","article-title":"Prevalence of prostate cancer among men with a prostate-specific antigen level \u22644.0 ng per milliliter","volume":"350","author":"Thompson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102363_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221084932","article-title":"Prostate cancer screening, diagnostic, treatment procedures and costs in Sub-Saharan Africa: a situational analysis","volume":"29","author":"Makau-Barasa","year":"2022","journal-title":"Cancer Control"},{"key":"10.1016\/j.clgc.2025.102363_bib0025","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/20514158211059057","article-title":"Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways","volume":"16","author":"Lophatananon","year":"2023","journal-title":"J Clin Urol"},{"key":"10.1016\/j.clgc.2025.102363_bib0026","first-page":"15","article-title":"The South African prostate cancer screening guidelines","volume":"114","author":"John","year":"2024","journal-title":"S Afr Med J"},{"key":"10.1016\/j.clgc.2025.102363_bib0027","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0022-5347(17)40079-6","article-title":"Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume, and benign hyperplasia","volume":"143","author":"Partin","year":"1990","journal-title":"J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:52:44Z","timestamp":1752609164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1558767325000643"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102363","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Sensitivity and Specificity of Total Prostate Specific Antigen in the Diagnosis of Prostate Cancer in a Resource-Limited African Setting: A 5-Year Review in a Kenyan Hospital","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102363"}}